Boehringer Ingelheim acquiring NBE-Therapeutics for €1.18 billion

Venture Leader Life Sciences and TOP 100 company NBE-Therapeutics acquired for €1.18 billion by Boehringer Ingelheim. Boehringer Ingelheim to strengthen its cancer pipeline portfolio with novel antibody-drug conjugates

NBE-Therapeutics, a Swiss biotech company based in Basel and founded in 2012 with the vision of developing next-generation immune-stimulatory antibody-drug conjugate (iADCTM) products. NBE advances its products to clinical proof of concept with the goal of improving treatment options for cancer patients. The company leverages proprietary platforms covering all aspects of ADC development: its Transpo-mAb DisplayTM technology for antibody discovery, its SMAC-TechnologyTM for site-specific payload conjugation of toxins to antibodies, and a novel highly effective, and immune-stimulatory anthracycline-based toxin platform.

The total value of the transaction is €1.18 billion including success-related clinical and regulatory milestones. Bertrand Damour, CEO at NBE-Therapeutics says, “I am very proud of the work done by the entire NBE Therapeutics team. The recognition of our first-class AWK expertise by Boehringer Ingelheim is very important to us. This transaction is a validation of our platform and its potential for next-generation cancer therapies". 

NBE-Therapeutics has been supported by Venture Leaders in 2003 and listed as TOP 100 company in 2013, 2014 and 2017.